In leaked results from a University of Chicago study, Gilead Sciences Inc.’s antiviral remdesivir showed large improvements in some patients with the most severe form of COVID-19, the respiratory disease caused by SARS-CoV-2.
Out of an initial 125 patients who received the drug in the trial, one of two Phase III clinical programs...






